|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2004-11-8
|
|
pubmed:abstractText |
Although the platelet count does not correlate with the rate of thrombosis, there is evidence that a strict control of the platelet count decreases the incidence of thromboembolic complications in essential thrombocythemia. In the current study, the authors evaluated the efficacy and tolerability of anagrelide in thrombocytosis associated with myeloproliferative disorders.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2004 American Cancer Society
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2239-46
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15476273-Adult,
pubmed-meshheading:15476273-Aged,
pubmed-meshheading:15476273-Aged, 80 and over,
pubmed-meshheading:15476273-Blood Platelets,
pubmed-meshheading:15476273-Female,
pubmed-meshheading:15476273-Fibrinolytic Agents,
pubmed-meshheading:15476273-Humans,
pubmed-meshheading:15476273-Male,
pubmed-meshheading:15476273-Middle Aged,
pubmed-meshheading:15476273-Myeloproliferative Disorders,
pubmed-meshheading:15476273-Platelet Count,
pubmed-meshheading:15476273-Quinazolines,
pubmed-meshheading:15476273-Thrombocytosis,
pubmed-meshheading:15476273-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
|
|
pubmed:affiliation |
Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
